The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in ...